- Home
- EVAX vs PT Comparison
EVAX vs PT Comparison
Compare EVAX & PT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- PT
- Stock Information
- Founded
- EVAX 2008
- PT 2012
- Country
- EVAX Denmark
- PT China
- Employees
- EVAX N/A
- PT N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- PT Computer Software: Programming Data Processing
- Sector
- EVAX Health Care
- PT Technology
- Exchange
- EVAX Nasdaq
- PT Nasdaq
- Market Cap
- EVAX 16.3M
- PT 15.2M
- IPO Year
- EVAX 2021
- PT 2018
- Fundamental
- Price
- EVAX $2.53
- PT $1.04
- Analyst Decision
- EVAX Strong Buy
- PT
- Analyst Count
- EVAX 3
- PT 0
- Target Price
- EVAX $33.33
- PT N/A
- AVG Volume (30 Days)
- EVAX 6.8M
- PT 30.7K
- Earning Date
- EVAX 03-26-2025
- PT 11-08-2024
- Dividend Yield
- EVAX N/A
- PT N/A
- EPS Growth
- EVAX N/A
- PT N/A
- EPS
- EVAX N/A
- PT N/A
- Revenue
- EVAX $3,295,000.00
- PT $4,479,352.00
- Revenue This Year
- EVAX $9,039.73
- PT N/A
- Revenue Next Year
- EVAX $1.47
- PT N/A
- P/E Ratio
- EVAX N/A
- PT N/A
- Revenue Growth
- EVAX N/A
- PT N/A
- 52 Week Low
- EVAX $2.22
- PT $0.71
- 52 Week High
- EVAX $22.05
- PT $1.25
- Technical
- Relative Strength Index (RSI)
- EVAX 40.91
- PT 55.60
- Support Level
- EVAX $2.43
- PT $0.93
- Resistance Level
- EVAX $2.80
- PT $1.15
- Average True Range (ATR)
- EVAX 0.31
- PT 0.06
- MACD
- EVAX 0.07
- PT 0.01
- Stochastic Oscillator
- EVAX 16.94
- PT 57.69
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
About PT Pintec Technology Holdings Limited
Pintec Technology Holdings Ltd is a technology platform that provides financial services in China in terms of loan volume facilitated. The company connects business partners and financial partners on its open platform and enables them to provide financial services to end-users. Its products include installment loans, personal loans, wealth management, insurance brokerage, SME loans, and others. The company generates its revenue from technical service fees also by providing financing for these borrowers and earn installment service fees, They earn wealth management services fees and commission on financial products.